 The FDA has signed off TScan Therapeutics Incs NASDAQ: TCRX investigational new drug IND application for TSC-100 in hematologic malignancies patients undergoing allogeneic hematopoietic cell transplantation HCT. The target of TSC-100 is the minor histocompatibility antigen HA-1, which is a lineage-specific antigen found on blood cells. 